Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity.
- Poplin, Elizabeth
- Wasan, Harpreet
- Rolfe, Lindsey
- Raponi, Mitch
- Ikdahl, Tone
- Bondarenko, Ihor
- Davidenko, Irina
- Bondar, Volodymyr
- Garin, August
- Boeck, Stefan
- Ormanns, Steffen
- Heinemann, Volker
- Bassi, Claudio
- Evans, T R Jeffrey
- Andersson, Roland
- Hahn, Hejin
- Picozzi, Vince
- Dicker, Adam
- Mann, Elaina
- Voong, Cynthia
- Kaur, Paramjit
- Isaacson, Jeff
- Allen, Andrew
Publication date
January 2013
DOI Publisher
American Society of Clinical Oncology (ASCO) ISSN
0732-183XAbstract
Gemcitabine requires transporter proteins to cross cell membranes. Low expression of human equilibrative nucleoside transporter-1 (hENT1) may result in gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC). CO-101, a lipid-drug conjugate of gemcitabine, was rationally designed to enter cells independently of hENT1. We conducted a randomized controlled trial to determine whether CO-101 improved survival versus gemcitabine in patients with metastatic PDAC (mPDAC) with low hENT1. The study also tested the hypothesis that gemcitabine is more active in patients with mPDAC tumors with high versus low hENT1 expression
Add to ORKG